Mulling Bernanke's ...
Health Care: Health Services
Ironwood Pharmaceuticals Inc. (IRWD: NASDAQ)
$12.14 -0.29 | -2.33%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 12.14 |
| 52 Week High | 19.67 |
| 52 Week Low | 10.01 |
| Avg. Daily Vol. (Mil) | 1.17 |
| Beta (3 year) | 1.74 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,136.77 |
| Shares Out (Mil) | 120.12 |
| Float (Mil) | 51.44 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.90 |
| Current Ratio | 4.40 |
| LT Debt/ Equity | 2.99 |
| Total Debt / Equity | 2.99 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 10.32 |
| Price/Book | 24.92 |
| Price/Cash Flow | -12.40 |
| Per Share Data | |
| Earnings | -1.24 |
| Sales | 1.18 |
| Book Value | 0.49 |
| Cash Flow | -0.98 |
| Business Summary | |
|---|---|
| Ironwood Pharmaceuticals, Inc. is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. | |
| General Information | |
| 301 Binney Street
Cambridge, MA 02142 |
|
| www.ironwoodpharma.com | |
| Industry : Health Services | |
| Sector: Health Care | |
| Employees: 530 | |
| CEO: Peter M. Hecht,PhD | |
| Short Interest | |
| Current Month (Mil) | 15.21 |
| Previous Month (Mil) | 17.09 |
| Short Interest Ratio (Days) | 10.80 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -40.30 |
| Return on Investments | -56.00 |
| Profitability | |
| Gross Margin | 98.40 |
| EBIT Margin | -98.20 |
| Profit Margin | -92.70 |
Portfolios with IRWD
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Rising On Unusual Vo...
- Contributor10 Pharma Stocks With Upside
- ProBridger Management
- ContributorRocket Stocks for the Week ...
- ContributorBarron's Insider Purchases ...
Latest IRWD Headlines from TheStreet
- Short Interest In Ironwood Pharmaceuticals Moves 11% Lower 06.13.13 | 02:06 pm
- 4 Stocks Underperforming Today In The Health Services Industry 06.12.13 | 01:06 pm
- Ironwood Pharmaceuticals Is Now Oversold (IRWD) 05.22.13 | 04:05 pm
- Ironwood Pharmaceuticals Enters Oversold Territory (IRWD) 05.01.13 | 12:05 pm
- 3 Stocks Underperforming Today In The Health Services Industry 04.25.13 | 01:04 pm
- Ironwood's Constipation Drug Sales Disappoint 04.23.13 | 08:04 am
- Top Insider Trades: ATVI, SCS, KSS, IRWD 04.03.13 | 07:04 am
- Analysts' Actions: FCX IRWD RIG SCHW ULTA 03.15.13 | 08:03 am
- Cramer's 'Mad Money' Recap: The Bullish Facts 01.17.13 | 08:01 pm
- Ironwood Pharmaceuticals Inc. Stock Downgraded (IRWD) 01.17.13 | 04:01 am
Press Releases for IRWD
- Edward Owens, Ironwood Board Of Directors (Photo: Business Wire) - Business Wire 03.04.13 | 08:03 am
- Ironwood Pharmaceuticals To Present At Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.25.13 | 04:02 pm
- Mark Currie, Ph.D., Senior Vice President, CSO, And President Of R&D Of Ironwood Pharmaceuticals, Inc. (Photo: Business Wire) - Business Wire 02.11.13 | 09:02 am
- Ironwood Pharmaceuticals Provides Fourth Quarter 2012 Investor Update - Business Wire 01.15.13 | 07:01 am
- Ironwood Pharmaceuticals To Host Fourth Quarter 2012 Investor Update Call - Business Wire 01.10.13 | 04:01 pm
- Ironwood Completes $175 Million Debt Offering - Business Wire 01.04.13 | 10:01 am
- Ironwood Pharmaceuticals To Present At J.P. Morgan Healthcare Conference - Business Wire 01.02.13 | 04:01 pm
- FACT SHEET -- Chronic Idiopathic Constipation - Business Wire 12.17.12 | 08:12 am
- Protagonist And Ironwood Expand Peptide Drug Discovery Collaboration - Business Wire 12.06.12 | 08:12 am
- Constella® (linaclotide) Approved In Europe For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)in Adults - PR Newswire 11.28.12 | 10:11 am
Partner Headlines for IRWD
- Pre-Market Most Active for May 22, 2013 : NTAP, PFE, NMR, RDS/A, RDS/B, NOK, SNE, PGTI, IRWD, GILD, VOD, ZNGA - NASDAQ 05.22.13 | 12:05 pm
- EU Approval for Ironwood's Constella - Analyst Blog - Zacks 11.30.12 | 02:11 pm
- Earnings Scorecard: Forest Labs - Analyst Blog - Zacks 10.26.12 | 06:10 pm
- Ironwood and AstraZeneca Announce Linaclotide Collaboration for China - Benzinga 10.23.12 | 09:10 am
- FDA OK's Forest-Ironwood's Linzess - Analyst Blog - NASDAQ 08.31.12 | 09:08 pm
- FDA OK's Forest-Ironwood's Linzess - Analyst Blog - Zacks 08.31.12 | 05:08 pm
- Hedging Ironwood before ruling - NASDAQ 08.28.12 | 09:08 am
- Ironwood Pharmaceuticals, Earnings Call INSIGHTS: Huge Opportunity in CC, Feeling Good About Commercial Readiness - Wall St. Cheat Sheet 07.18.12 | 11:07 am
- Delay in Forest Drug FDA Action Date - Analyst Blog - Zacks 03.30.12 | 05:03 pm
- Forest-Janssen Sue Generic Players - Analyst Blog - Zacks 03.16.12 | 07:03 pm
